更新于：2024-11-01

Pinguecula

睑裂黄斑

更新于：2024-11-01

基本信息

别名

Pinguecula、Pinguecula (disorder)、Pingueculas

+ [9]

简介

A yellowish thickened lesion on the conjunctiva near the CORNEA representing a benign degenerative change in the CONJUNCTIVA caused by the leakage and deposition of certain blood proteins through the permeable capillaries near the LIMBUS.

关联

项与睑裂黄斑相关的药物

CBT-004

靶点

PDGFR x VEGFR

作用机制

PDGFR拮抗剂 [+1]

在研机构

Cloudbreak Therapeutics LLC初创企业

原研机构

拨云生物医药科技（广州）有限公司

在研适应症

睑裂黄斑

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

项与睑裂黄斑相关的临床试验

NCT04884256 / Recruiting临床2期

A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-004 Ophthalmic Emulsion in Patients With Vascularized Pinguecula

STUDY DESIGN:
Structure:
Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
Duration of Treatment:
4 weeks of study treatment with 4 weeks follow-up observations.
Control:
Vehicle for CBT-004 (hereafter referred to as Vehicle).
Masking:
Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications.
Dosage/Dose regimen:
One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye.

开始日期2023-12-21

申办/合作机构

Cloudbreak Therapeutics LLC初创企业

IRCT20240702062306N1 / Completed临床3期IIT

Recurrence of pinguecula by ligation and subconjunctival bevacizumab (avastin) injection in short time

开始日期2020-11-05

申办/合作机构

Mazandaran University of Medical Sciences

100 项与睑裂黄斑相关的临床结果

登录后查看更多信息

100 项与睑裂黄斑相关的转化医学

登录后查看更多信息

0 项与睑裂黄斑相关的专利（医药）

登录后查看更多信息

107

项与睑裂黄斑相关的文献（医药）

2024-08-01·Canadian Journal of Ophthalmology

Can high-resolution optical coherence tomography provide an optical biopsy for ocular surface lesions?

Review

作者: Cohen, Noah K ; Greenfield, Jason A ; Herskowitz, William R ; Galor, Anat ; De Arrigunaga, Sofia ; Karp, Carol L

High-resolution optical coherence tomography (HR-OCT) has transformed the diagnosis and management of ocular surface lesions. Providing a detailed cross-sectional view of the cornea and conjunctiva, HR-OCT can be used to identify characteristic features of various benign and malignant ocular surface lesions, aiding in their diagnosis and guiding treatment. When incorporated into an ophthalmology clinic, HR-OCT provides morphological images of lesions in a noninvasive means, akin to an "optical biopsy". The characteristic HR-OCT features of several lesions have been well described in the literature, including for ocular surface squamous neoplasia, papilloma, melanoma, primary acquired melanosis, complexion associated melanosis, nevus, pterygium, pinguecula, lymphoma, and amyloidosis. HR-OCT can be used to differentiate between lesions with similar clinical features, lesions that co-exist on the same ocular surface, and atypically presenting lesions, such as pigmented ocular surface squamous neoplasia or amelanotic melanoma. The management of ocular surface lesions has been transformed by the implementation of HR-OCT, providing clinicians with the ability to monitor tumor response to topical chemotherapies, follow previously excised lesions for recurrence, and map out tumor borders intraoperatively. While there are some limitations to HR-OCT, including imaging of thick or deep lesions, it has become an essential tool for ocular oncologists in the management of ocular surface lesions.

2024-03-01·International Journal of Surgery Case Reports

Variable presentations of six conjunctival/limbal ocular surface squamous neoplasia (OSSN) cases: How good is our clinical judgment evidenced by the correlation to the histopathological findings and diagnosis?

Article

作者: Al-Dahmash, Saad A ; Alharbi, Ibrahim ; Alfawaz, Abdullah M ; Alkatan, Hind M ; Otaif, Wael

INTRODUCTIONOcular surface squamous neoplasia (OSSN) may have atypical or unusual presentations and may attain large sizes especially in cases of delayed presentation resulting in late diagnosis, treatment, and eventual guarded visual prognosis. We are reporting an interesting cases series of OSSN with variable clinical presentations to highlight the importance of the pre-operative clinical judgment and tissue diagnosis.PRESENTATION OF CASESSix patients (4 females and 2 males; mean age 59 years; range 42-79 years) were included with suspicious conjunctival lesions. The maximum dimension of the lesions was 17 mm. The initial suspected pre-operative clinical diagnosis -other than OSSN- included pterygium/pinguecula (n = 2), benign squamous papilloma (n = 1), cyst versus pyogenic granuloma (n = 1), and lymphoma (n = 1). This work has been reported in line with the PROCESS criteria.DISCUSSIONThe final histopathological diagnosis was unexpectedly invasive squamous cell carcinoma (SCC) in 4, one SCC in-situ, and squamous dysplasia in one. The primary treatment included MMC 0.02 % for 2 cycles for chemo-reduction in one of the cases where OSSN was suspected. Excisional biopsy was performed eventually for all lesions with application of one or more of the following modalities: MMC 0.02 %, absolute alcohol 99 %, and cryotherapy to the conjunctival margin. No tumor recurrence was noted in any of the patients after an average period of follow-up of 26 months. Even though the outcome was good, tumor-related morbidity and delay in the referral by general ophthalmologists are to be considered.CONCLUSIONConjunctival OSSN has wide presentation clinically and can be challenging in terms of diagnosis. Histopathological evaluation is essential for a definitive diagnosis and treatment. Accurate clinical diagnosis might affect the management plan with consideration for topical therapeutic modalities, however, these cases are best managed by wide excision using the no-touch technique and double-freeze-thaw cryotherapy to the conjunctiva with consideration of topical chemotherapy.

2022-06-01·Klinische Monatsblätter für Augenheilkunde

Bindehautdegenerationen und -neoplasien

Article

作者: Reinhard, Thomas ; Gasser, Laura ; Auw-Hädrich, Claudia